D'Avino, Alessandro
 Distribuzione geografica
Continente #
EU - Europa 1.181
NA - Nord America 915
AS - Asia 182
SA - Sud America 5
AF - Africa 2
OC - Oceania 2
Totale 2.287
Nazione #
US - Stati Uniti d'America 899
DE - Germania 394
PL - Polonia 211
FR - Francia 146
SE - Svezia 142
CN - Cina 117
IT - Italia 105
UA - Ucraina 80
IN - India 38
IE - Irlanda 35
GB - Regno Unito 31
FI - Finlandia 21
CA - Canada 15
TR - Turchia 13
IR - Iran 6
BE - Belgio 4
BR - Brasile 3
DK - Danimarca 3
HK - Hong Kong 3
AU - Australia 2
CL - Cile 2
KR - Corea 2
NL - Olanda 2
RU - Federazione Russa 2
AT - Austria 1
EE - Estonia 1
ET - Etiopia 1
GR - Grecia 1
HR - Croazia 1
JP - Giappone 1
MM - Myanmar 1
MX - Messico 1
RO - Romania 1
SG - Singapore 1
TN - Tunisia 1
Totale 2.287
Città #
Kraków 210
Chandler 203
Jacksonville 67
Ashburn 64
New York 46
San Mateo 42
Redmond 37
Dublin 35
Ann Arbor 29
Milan 28
Cattolica 27
Nürnberg 26
Wilmington 26
Nanjing 25
Dearborn 24
Lawrence 18
Woodbridge 18
Houston 17
Boston 15
Izmir 13
Nanchang 13
Ottawa 13
Lancaster 12
Changsha 11
Fairfield 11
Redwood City 11
Beijing 9
Shenyang 9
Kunming 8
Rome 8
Falls Church 7
Augusta 6
Chicago 6
Fremont 6
Hebei 6
Mountain View 6
Shanghai 6
Hangzhou 5
Leawood 5
Los Angeles 5
Marseille 5
Munich 5
Seattle 5
Tianjin 5
Verona 5
Bari 4
Bremen 4
Brussels 4
Cambridge 4
Guangzhou 4
Jinan 4
Kish 4
Pune 4
University Park 4
Washington 4
Boardman 3
Fuzhou 3
Modena 3
Paris 3
Princeton 3
Ardabil 2
Auburn Hills 2
Busto Arsizio 2
Clearwater 2
Cupertino 2
Helsinki 2
Henderson 2
Hong Kong 2
Jiaxing 2
San Jose 2
Simi Valley 2
Toronto 2
Zhengzhou 2
Addis Ababa 1
Amsterdam 1
Andover 1
Bangalore 1
Bologna 1
Downers Grove 1
Edinburgh 1
Groningen 1
Hefei 1
Lanzhou 1
London 1
Millbury 1
Monmouth Junction 1
New Orleans 1
Ningbo 1
Petriolo 1
Philadelphia 1
Phoenix 1
Phoenixville 1
Raleigh 1
San Diego 1
Sassari 1
Secunderabad 1
Singapore 1
Sovicille 1
São Paulo 1
Tallinn 1
Totale 1.266
Nome #
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 192
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 164
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 159
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 152
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance 144
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 142
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 125
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 125
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 117
Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy 107
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study 106
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 100
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study 96
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 96
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 83
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients 76
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 76
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 71
Coccidioidomycosis of cervical lymph nodes in an HIV-infected patient with immunologic reconstitution on potent HAART: a rare observation in a nonendemic area 69
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 58
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir 50
Totale 2.308
Categoria #
all - tutte 6.475
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.475


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201945 0 0 0 0 0 0 0 0 0 0 30 15
2019/2020321 76 16 17 7 33 25 16 30 26 21 38 16
2020/2021162 8 20 4 15 19 10 12 1 35 5 30 3
2021/2022245 18 18 6 20 11 19 3 44 13 28 29 36
2022/2023457 65 77 29 79 35 54 8 45 57 1 5 2
2023/2024198 12 66 4 26 14 59 10 0 3 3 1 0
Totale 2.308